Thomas Gonatopoulos-Pournatzis

Has grant

NIH Stadtman Investigator

National Institutes of Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Beyond virus sensing: Rig-like receptors in biomolecular condensates

Open Date: 2025-01-01

Close Date: 2027-12-31

Grant: Close

Identify and Characterize Phenotypically Relevant Alternatively Spliced Exons

Open Date: 2021-01-01

Close Date: 2024-01-01

Grant: Close

Map Novel Regulatory Networks that Control Alternative Splicing

Open Date: 2020-01-01

Close Date: 2024-01-01

Grant: Close

Development and application of a novel CRISPR-based platform for the comprehensive identification of alternative splicing events underlying cell proliferation and tumorigenesis

Open Date: 2018-04-01

Close Date: 2019-03-31

Grant: Close

Systematic identification and characterization of neuronal alternative splicing networks underlying nervous system development and disorders

Open Date: 2018-04-01

Close Date: 2021-03-31

Articles (8)

Year:

2026

Alternative splicing is a pervasive gene regulatory mechanism critical for diversifying the human proteome. To systematically investigate its role in cell fate determination, we develop scCHyMErA-Seq, a scalable CRISPR-based exon deletion screening platform integrated with 10x Genomics single-cell transcriptomic readouts. This tool enables efficient exon deletion while simultaneously capturing Cas9/Cas12a guides and polyadenylated transcripts at single-cell resolution. Applying scCHyMErA-Seq to high-throughput profiling of alternative cassette exons, we identify numerous exons with pronounced regulatory effects on gene expression and cell cycle progression. Analysis of the alternative NRF1 exon-7 demonstrates that its inclusion modulates NRF1’s regulatory function by influencing its recruitment to the promoters of target genes. Importantly, gene expression profiles generated using scCHyMErA-Seq accurately recapitulate findings from traditional, labor-intensive orthogonal methods, while offering enhanced scalability and efficiency. Overall, scCHyMErA-Seq represents a versatile platform for systematically unraveling the functional impact of alternative splicing by directly linking specific splicing variants to transcriptional phenotypes.

Year:

2026

Intron retention (IR) is a form of alternative splicing in which an intron that is typically spliced out is retained in the mature RNA. Despite emerging evidence of widespread IR in protein-coding genes and lncRNAs, the underlying molecular mechanisms remain unclear. Here, we developed a genome-wide screen termed CRASP-seq, to investigate the mechanisms underlying IR in the lncRNA PURPL. Unexpectedly, the top hit was the essential splicing activator U2AF2 that promoted IR in PURPL by directly binding to a weak polypyrimidine tract. U2AF2 promoted IR in additional transcripts, including the nuclear speckle-localized MALAT1 whose localization to nuclear speckles was disrupted upon U2AF2 depletion. Importantly, retention of a specific endogenous MALAT1 intron was critical for its nuclear speckle localization and promoting cell migration. These findings uncover a non-canonical function of U2AF2 in promoting IR and reveal how IR contributes to the subcellular localization and functions of PURPL and MALAT1 .

Year:

2026

Year:

2025

Year:

2025

Despite progress in understanding pre-mRNA splicing, the regulatory mechanisms controlling most alternative splicing events remain unclear. We developed CRASP-Seq, a method that integrates pooled CRISPR-based genetic perturbations with deep sequencing of splicing reporters, to quantitively assess the impact of all human genes on alternative splicing from a single RNA sample. CRASP-Seq identifies both known and novel regulators, enriched for proteins involved in RNA splicing and metabolism. As proof-of-concept, CRASP-Seq analysis of an LMNA cryptic splicing event linked to progeria uncovered Z NF 207, primarily known for mitotic spindle assembly, as a regulator of progerin splicing. ZNF207 depletion enhances canonical LMNA splicing and decreases progerin levels in patient-derived cells. High-throughput mutagenesis further showed that ZNF207’s zinc finger domain broadly impacts alternative splicing through interactions with U1 snRNP factors. These findings position ZNF207 as a U1 snRNP auxiliary factor and demonstrate the power of CRASP-Seq to uncover key regulators and domains of alternative splicing. Main Points CRASP-Seq: RNA-coupled CRISPR screen quantifying gene and domain impact on splicing Profiling of five events identified 370 genes influencing alternative splicing ZNF207 regulates splicing by interacting with U1 snRNP via its zinc-finger domains ZNF207 depletion corrects LMNA aberrant splicing causing progeria

Year:

2025

Year:

2024

Year:

2024

Collaborators (6)

Jean-Philippe Gagne

Professionnel de recherche

Université Laval

CANADA
View details

Giulia Bertolin

PI / permanent researcher

CNRS Délégation Bretagne et Pays de Loire

FRANCE
View details

Natasha Caplen

Principal Investigator

National Cancer Institute

UNITED STATES
View details

Alexendar Perez

University of California, San Francisco

UNITED STATES
View details

Tom Misteli

National Cancer Institute

UNITED STATES
View details

Michael Aregger

NIH Stadtman Investigator

National Institutes of Health

UNITED STATES
View details